Lamivudin/Zidovudin Aurobindo (Zidovudine, Lamivudine)

Lamivudine is a nucleoside analogue that, after intracellular phosphorylation, mimics natural nucleosides and is incorporated into viral DNA by reverse transcriptase. This incorporation halts DNA chain elongation, preventing the virus from replicating effectively.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s age, weight, renal function, and overall treatment plan. Healthcare professionals should follow current HIV treatment guidelines when selecting the appropriate regimen.

Safety data for lamivudine and zidovudine in pregnancy are limited, and the product’s pregnancy category is not established. Clinicians must weigh potential benefits against risks and consider alternative therapies when treating pregnant or nursing patients.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with single‑agent regimens, the lamivudine/zidovudine combination offers a convenient two‑drug tablet that reduces pill burden. While newer agents may have improved resistance profiles, this combination remains a cost‑effective option in many treatment guidelines, especially where access to newer drugs is limited.

Lamivudin/Zidovudin Aurobindo tablets should be stored at ambient temperature below 25 °C, in the original packaging, and protected from moisture and direct sunlight. Do not store in a refrigerator or freezer.

The medication is taken orally, usually with or without food, as directed by the prescriber. Patients should swallow the tablet whole with a glass of water and follow the dosing schedule prescribed by their healthcare provider.

Serious adverse events include severe lactic acidosis, hepatotoxicity, and hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should be educated to report symptoms like unexplained fatigue, abdominal pain, jaundice, or skin rash promptly.

Individuals with known hypersensitivity to lamivudine, zidovudine, or any component of the tablet should avoid this medication. Clinicians should also exercise caution in patients with significant liver disease, severe anemia, or mitochondrial disorders.